Search

Displaying results 2861 - 2870 of 6835 in total
  1. Drug

    Geraniol

    go.drugbank.com/drugs/DB14183
    Approved

    It is emitted from the flowers of many species of plant and is commonly used by the food, fragrance, and cosmetic industry[L3333]. … Sensitivity to geraniol may be identified with a clinical patch test.

    Synonyms: t-geraniol
  2. Drug

    Fospropofol

    go.drugbank.com/drugs/DB06716
    ApprovedIllicitInvestigationalWithdrawn

    Unlike propofol, does not cause injection-site pain as it is unable to activate TRPA1. FDA approved in December 2008. … Fospropofol is a water soluble prodrug and is converted to propofol in the liver. Fospropofol is a short acting hypnotic/sedative/anesthetic agent.

  3. Drug

    Penpulimab

    go.drugbank.com/drugs/DB16747
    ApprovedInvestigational

    [A273843,A273848] Penpulimab-kcqx was approved by the US FDA in April 2025 for the treatment of nasopharyngeal carcinoma in select patients.[L52993,L52998] … The use of an IgG1 backbone - as opposed to an IgG4 backbone as is typical in other anti-PD-1 antibodies like [nivolumab] - is intended to reduce the risk of immune-related adverse events.

  4. Drug

    Mannitol

    go.drugbank.com/drugs/DB00742
    ApprovedInvestigational

    this indication under the name BRONCHITOL® by Chiesi USA Inc. … On October 30, 2020, mannitol was approved by the FDA as add-on maintenance therapy for the control of pulmonary symptoms associated with cystic fibrosis in adult patients and is currently marketed for

  5. Drug

    Avacopan

    go.drugbank.com/drugs/DB15011
    ApprovedInvestigational

    [L39850] Avacopan was approved by Health Canada on April 20, 2022.[L41650] … [A240269, A240329, L38919] Avacopan was granted FDA approval on October 8, 2021, and is currently marketed under the name TAVNEOS by ChemoCentryx, Inc.

  6. Drug

    Pacritinib

    go.drugbank.com/drugs/DB11697
    ApprovedInvestigational

    [L40793] The underlying cause of primary MF is unknown, but secondary MF can arise in patients with a history of polycythemia vera or essential thrombocythemia. … Myelofibrosis (MF) is a rare disorder characterized by hematopoietic abnormalities and fibrosis within the bone marrow.

  7. Drug

    Fibrinolysin

    go.drugbank.com/drugs/DB05254
    Investigational

    Fibrinolysin consists of two polypeptide chains, one light and one heavy, linked by a disulfide bond. … The combination is available as ointment containing 1 BU (Biological Unit) Fibrinolysin and 666 BUs desoxyribonuclease per gram.

  8. Drug

    Afamelanotide

    go.drugbank.com/drugs/DB04931
    Approved

    [L9086] It differs structurally from its endogenous counterpart by only two amino acids - these structural differences improve biological efficacy by imparting a greater affinity for its target and a longer

  9. Drug

    Ambenonium

    go.drugbank.com/drugs/DB01122
    ApprovedWithdrawn

    Ambenonium is a cholinesterase inhibitor. It is used in the management of myasthenia gravis.

  10. Drug

    Ritonavir

    go.drugbank.com/drugs/DB00503
    ApprovedInvestigational

    Any HCV/HIV-1 co-infected patients treated with ritonavir-containing combination therapies should also be on a suppressive antiretroviral drug regimen to reduce the risk of HIV-1 protease inhibitor drug … Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors